After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

• https://x.com/RHEUMarampa/status/1982499968767185041/photo/1

#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R

• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1
• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1

#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T Zorpocabtagene-autoleucel/MB19.1: - 22/24 high degree efficacy - no relapse - no high grade CRS/ICANS *Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl

• https://x.com/Yuz6Yusof/status/1982496709860344006/photo/1

Real-world JAK persistence in RA is low: <30% at 2 years across Medicare & Marketscan data (n≈20K). Baricitinib lowest persistence; TOF & UPA slightly higher. Oral convenience hasn’t solved long-term adherence. Why? Safety, cost, access? @RheumNow #ACR25 A#0369

Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP

• https://x.com/EBRheum/status/1982494684107727105/photo/1

Only 32% of RA pts were satisfied with current txs. In a discrete choice experiment of 354 US pts, many preferred a vagus nerve stimulator over another biologic/JAKi, especially those with prior tx failures. Cost, function, and fatigue drove preferences. @RheumNow #ACR25 A#0370

Icotrokinra, a first-in-class targeted oral peptide IL-23R inhibitor, cleared scalp (66%), genital (77%), and overall skin (57%) PsO vs placebo at Week 16. Basket trial design enabled targeted evaluation. Safety profile favorable. Abstract 0555 @RheumNow #ACR25

Phenotypes of GCA: Pt dx by PET compared to TA biopsy were: - younger -longer disease before dx -more frequent extremity claudication (still overall low) -less cranial / TA sx @RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq

• https://x.com/Dr_Brian_MD/status/1982492391803408736/photo/1

Avacopan in the real world: we need to be braver If we want to get steroid-sparing benefit in AAV, we need to trust it claims data shows modest PNL reduction with avacopan some manifestations are harder to taper in, but others we just need to be bolder #ACR25 ABST0726 @RheumNow https://t.co/51nGdpR2db

• https://x.com/drdavidliew/status/1982488060941213929/photo/1

Can the blood reflect what’s happening in the joint? In early RA, 11 synovial proteins mirrored serum levels, forming an inflammatory signature linked to disease activity and csDMARD response. High-signature pts had stronger treatment responses (AUC>0.8) @RheumNow #ACR25 A#0070

A systematic review by Dr. SRamiro et al evaluated efficacy of b/tsDMARDs on peripheral axSpA Majority on bDMARDs (TNFi, n=24; IL-17, n=13) Most of the SMDs were small --> b/tsDMARDs showed small to moderate effects on peripheral arthritis & enthesitis. #ACR25 @RheumNow Abs0588 https://t.co/yGXcqhZ1Uv

• https://x.com/RHEUMarampa/status/1982490153852833879/photo/1

Cool study using vasculitis patient-powered reserach network (VPPRN) "SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission Very important impacter of QOL in AAV #ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS

• https://x.com/EBRheum/status/1982490908848500816/photo/1
• https://x.com/EBRheum/status/1982490908848500816/photo/1

Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower sensitivity (79%) but better specificity (96%) @RheumNow #ACR25 Abstr#750 https://t.co/SIkAkEeYh1

• https://x.com/RichardPAConway/status/1982484365751075203/photo/1

ASAS recommends standardised reporting for 20 key outcomes in axSpA trials, 10 for all studies, 10 specific to DMARD trials. Formats include mean (±SD), mean change, and categorical thresholds for ASDAS, ASAS-HI, and extra-musculoskeletal manifestations. 85% of ASAS members https://t.co/VQwPaTRIOl

• https://x.com/synovialjoints/status/1982484870388498728/photo/1

Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep advocating for trials in all populations! #ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc

• https://x.com/EBRheum/status/1982485372568482227/photo/1